Puma Bio (PBYI) Revenue & Revenue Breakdown
Puma Bio Revenue Highlights
Latest Revenue (Y)
$235.64M
Latest Revenue (Q)
$47.08M
Main Segment (Y)
Royalty
Main Geography (Y)
Royalty
Puma Bio Revenue by Period
Puma Bio Revenue by Year
| Date | Revenue | Change |
|---|---|---|
| 2023-12-31 | $235.64M | 3.35% |
| 2022-12-31 | $228.00M | -9.95% |
| 2021-12-31 | $253.20M | 12.48% |
| 2020-12-31 | $225.10M | -17.33% |
| 2019-12-31 | $272.30M | 8.49% |
| 2018-12-31 | $251.00M | 806.14% |
| 2017-12-31 | $27.70M | 100.00% |
| 2016-12-31 | - | 100.00% |
| 2015-12-31 | - | 100.00% |
| 2014-12-31 | - | 100.00% |
| 2013-12-31 | - | 100.00% |
| 2012-12-31 | - | -100.00% |
| 2011-12-31 | $-281.10K | 100.00% |
| 2010-12-31 | - | 100.00% |
| 2009-12-31 | - | 100.00% |
| 2008-12-31 | - | 100.00% |
| 2007-12-31 | - | - |
Puma Bio generated $235.64M in revenue during NA 2023, up 3.35% compared to the previous quarter, and up 93.88% compared to the same period a year ago.
Puma Bio Revenue by Quarter
| Date | Revenue | Change |
|---|---|---|
| 2024-06-30 | $47.08M | 7.58% |
| 2024-03-31 | $43.77M | -39.36% |
| 2023-12-31 | $72.18M | 28.62% |
| 2023-09-30 | $56.12M | 2.84% |
| 2023-06-30 | $54.57M | 3.40% |
| 2023-03-31 | $52.77M | -19.67% |
| 2022-12-31 | $65.70M | 15.06% |
| 2022-09-30 | $57.10M | -4.06% |
| 2022-06-30 | $59.52M | 30.13% |
| 2022-03-31 | $45.74M | -17.44% |
| 2021-12-31 | $55.40M | 19.80% |
| 2021-09-30 | $46.24M | -13.37% |
| 2021-06-30 | $53.38M | -45.62% |
| 2021-03-31 | $98.17M | 86.63% |
| 2020-12-31 | $52.60M | 3.64% |
| 2020-09-30 | $50.75M | -28.09% |
| 2020-06-30 | $70.58M | 37.81% |
| 2020-03-31 | $51.22M | -18.57% |
| 2019-12-31 | $62.90M | 11.52% |
| 2019-09-30 | $56.40M | 4.60% |
| 2019-06-30 | $53.92M | -45.59% |
| 2019-03-31 | $99.10M | 39.38% |
| 2018-12-31 | $71.10M | 13.58% |
| 2018-09-30 | $62.60M | 23.31% |
| 2018-06-30 | $50.77M | -23.68% |
| 2018-03-31 | $66.52M | 207.94% |
| 2017-12-31 | $21.60M | 255.44% |
| 2017-09-30 | $6.08M | 100.00% |
| 2017-06-30 | - | 100.00% |
| 2017-03-31 | - | 100.00% |
| 2016-12-31 | - | 100.00% |
| 2016-09-30 | - | 100.00% |
| 2016-06-30 | - | 100.00% |
| 2016-03-31 | - | 100.00% |
| 2015-12-31 | - | 100.00% |
| 2015-09-30 | - | 100.00% |
| 2015-06-30 | - | 100.00% |
| 2015-03-31 | - | 100.00% |
| 2014-12-31 | - | 100.00% |
| 2014-09-30 | - | 100.00% |
| 2014-06-30 | - | 100.00% |
| 2014-03-31 | - | 100.00% |
| 2013-12-31 | - | 100.00% |
| 2013-09-30 | - | 100.00% |
| 2013-06-30 | - | 100.00% |
| 2013-03-31 | - | 100.00% |
| 2012-12-31 | - | 100.00% |
| 2012-09-30 | - | 100.00% |
| 2012-06-30 | - | 100.00% |
| 2012-03-31 | - | 100.00% |
| 2011-12-31 | - | 100.00% |
| 2011-09-30 | - | 100.00% |
| 2011-06-30 | - | 100.00% |
| 2011-03-31 | - | 100.00% |
| 2010-12-31 | - | 100.00% |
| 2010-09-30 | - | 100.00% |
| 2010-06-30 | - | 100.00% |
| 2010-03-31 | - | 100.00% |
| 2009-12-31 | - | 100.00% |
| 2009-09-30 | - | 100.00% |
| 2009-06-30 | - | 100.00% |
| 2009-03-31 | - | 100.00% |
| 2008-12-31 | - | 100.00% |
| 2008-09-30 | - | 100.00% |
| 2008-06-30 | - | 100.00% |
| 2008-03-31 | - | 100.00% |
| 2007-12-31 | - | - |
Puma Bio generated $47.08M in revenue during Q2 2024, up 7.58% compared to the previous quarter, and up 89.21% compared to the same period a year ago.
Puma Bio Revenue Breakdown
Puma Bio Revenue Breakdown by Product
Annual Revenue by Product
| Product/Service | Dec 20 | Dec 19 | Dec 18 |
|---|---|---|---|
| License | $2.50M | $60.25M | $50.50M |
| Royalty | $5.68M | $391.00K | - |
| Product | - | $211.62M | $200.49M |
Puma Bio's latest annual revenue breakdown by segment (product or service), as of Dec 20: Royalty (69.45%), and License (30.55%).
Quarterly Revenue by Product
| Product/Service | Jun 24 | Jun 21 | Mar 21 | Dec 20 | Sep 20 | Jun 20 | Mar 20 | Dec 19 | Sep 19 | Jun 19 | Mar 19 | Dec 18 | Sep 18 | Jun 18 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Royalty | $2.69M | $4.28M | $2.35M | $2.54M | $1.42M | $1.11M | $608.00K | $216.00K | $120.00K | $55.00K | - | - | - | - |
| Product | $44.40M | $48.86M | $50.02M | $48.77M | $48.61M | $58.71M | $53.48M | $53.86M | $45.57M | $61.08M | $52.63M | $50.77M | - | - |
| License | - | $250.00K | $2.50M | $2.70M | $20.70M | $2.00M | $4.00M | $2.75M | - | $53.50M | $10.00M | $10.00M | $30.50M | - |
Puma Bio's latest quarterly revenue breakdown by segment (product or service), as of Jun 24: Product (94.29%), and Royalty (5.71%).
Puma Bio Revenue Breakdown by Country
Annual Revenue by Country
| Country | Dec 20 | Dec 19 | Dec 18 |
|---|---|---|---|
| Royalty | $5.68M | $391.00K | - |
| License | $2.50M | $60.25M | $50.50M |
| Product | - | $211.62M | $200.49M |
Puma Bio's latest annual revenue breakdown by geography, as of Dec 20: Royalty (69.45%), and License (30.55%).
Quarterly Revenue by Country
| Country | Jun 21 | Mar 21 | Dec 20 | Sep 20 | Jun 20 | Mar 20 | Dec 19 | Sep 19 | Jun 19 | Mar 19 | Dec 18 | Sep 18 | Jun 18 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Royalty | $4.28M | $2.35M | $2.54M | $1.42M | $1.11M | $608.00K | $216.00K | $120.00K | $55.00K | - | - | - | - |
| Product | $48.86M | $50.02M | $48.77M | $48.61M | $58.71M | $53.48M | $53.86M | $45.57M | $61.08M | $52.63M | $50.77M | - | - |
| License | $250.00K | $2.50M | $2.70M | $20.70M | $2.00M | $4.00M | $2.75M | - | $53.50M | $10.00M | $10.00M | $30.50M | - |
Puma Bio's latest quarterly revenue breakdown by geography, as of Jun 21: Product (91.52%), Royalty (8.01%), and License (0.47%).
Puma Bio Peer Comparison by Revenue
| Ticker | Company | Last Year Revenue | Last Quarter Revenue |
|---|---|---|---|
| SRPT | Sarepta Therapeutics | $1.24B | $413.46M |
| PTCT | PTC Therapeutics | $937.82M | $186.70M |
| RARE | Ultragenyx Pharmaceutical | $434.25M | $147.03M |
| CHRS | Coherus BioSciences | $257.24M | $64.98M |
| PBYI | Puma Bio | $235.64M | $47.08M |
| HRTX | Heron Therapeutics | $127.04M | $46.54M |
| TSVT | 2seventy bio | $100.39M | $8.97M |
| ARVN | Arvinas | $78.50M | $76.50M |
| MGNX | MacroGenics | $58.75M | $10.80M |
| RVMD | Revolution Medicines, Inc. Warrant | $11.58M | - |
| CRNX | Crinetics Pharmaceuticals | $4.01M | $640.00K |
| IOVA | Iovance Biotherapeutics | $1.19M | $31.11M |
| VKTX | Viking Therapeutics | - | - |
| KURA | Kura Oncology | - | - |
| MDGL | Madrigal Pharmaceuticals | - | - |
| LRMR | Larimar Therapeutics | - | - |
| HEPA | Hepion Pharmaceuticals | - | - |
PBYI Revenue FAQ
What is Puma Bio’s yearly revenue?
Puma Bio's yearly revenue for 2023 was $235.64M, representing an increase of 3.35% compared to 2022. The company's yearly revenue for 2022 was $228M, representing a decrease of -9.95% compared to 2021. PBYI's yearly revenue for 2021 was $253.2M, representing an increase of 12.48% compared to 2020.
What is Puma Bio’s quarterly revenue?
Puma Bio's quarterly revenue for Q2 2024 was $47.08M, a 7.58% increase from the previous quarter (Q1 2024), and a -13.72% decrease year-over-year (Q2 2023). The company's quarterly revenue for Q1 2024 was $43.77M, a -39.36% decrease from the previous quarter (Q4 2023), and a -17.07% decrease year-over-year (Q1 2023). PBYI's quarterly revenue for Q4 2023 was $72.18M, a 28.62% increase from the previous quarter (Q3 2023), and a 9.86% increase year-over-year (Q4 2022).
What is Puma Bio’s revenue growth rate?
Puma Bio's revenue growth rate for the last 3 years (2021-2023) was -6.94%, and for the last 5 years (2019-2023) was -13.46%.
What are Puma Bio’s revenue streams?
Puma Bio's revenue streams in c 20 are License, and Royalty. License generated $2.5M in revenue, accounting 30.55% of the company's total revenue, down -95.85% year-over-year. Royalty generated $5.68M in revenue, accounting 69.45% of the company's total revenue, up 1353.20% year-over-year.
What is Puma Bio’s main source of revenue?
For the fiscal year ending Dec 20, the largest source of revenue of Puma Bio was Royalty. This segment made a revenue of $5.68M, representing 69.45% of the company's total revenue.